PERTH, Australia – Melbourne-based Starpharma Ltd. submitted a rolling submission of its Vivagel new drug application (NDA) to the FDA for preventing and treating recurrent bacterial vaginosis (rBV). With that submission, the biotech company joins a very limited club of Australian biotechs to bring their products all the way through to registration.